武汉大学人民医院，又名湖北省人民医院、武汉大学附属第一医院、武汉大学第一临床学院，是一家集医疗、教学、科研于一体的综合医疗机构，是武汉大学的三所附属医院之一，湖北省首批三级甲等医院之一。

During the past decade, Renmin Hospital of Wuhan University conducted 135 clinical trials. In the 10-year time frame, 135 clinical trials started and 12 clinical trials were completed, i.e. on average, 8.9% percent of trials that started reached the finish line to date. In the past 5 years, 102 clinical trials started and 9 clinical trials were completed. i.e. 8.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Renmin Hospital of Wuhan University" #1 sponsor was "Renmin Hospital of Wuhan University" with 45 trials, followed by "Boehringer Ingelheim" with 5 trials sponsored, "Eli Lilly and Company" with 5 trials sponsored, "Hoffmann-La Roche" with 5 trials sponsored and "Chengdu Kanghong Biotech Co., Ltd." with 5 trials sponsored. Other sponsors include 91 different institutions and companies that sponsored additional 79 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Renmin Hospital of Wuhan University" #1 collaborator was "Renmin Hospital of Wuhan University" with 14 trials as a collaborator, "LanZhou University" with 5 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator, "Hubei Hospital of Traditional Chinese Medicine" with 4 trials as a collaborator and "The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture" with 4 trials as a collaborator. Other collaborators include 236 different institutions and companies that were collaborators in the rest 198 trials.

According to Clinical.Site data, the most researched conditions in "Renmin Hospital of Wuhan University" are "Artificial Intelligence" (12 trials), "Gastrointestinal Disease" (5 trials), "COVID-19" (4 trials), "Coronary Artery Disease" (4 trials) and "Endoscopy" (4 trials). Many other conditions were trialed in "Renmin Hospital of Wuhan University" in a lesser frequency.

Most popular intervention types in "Renmin Hospital of Wuhan University" are "Drug" (87 trials), "Other" (17 trials), "Device" (15 trials), "Procedure" (15 trials) and "Biological" (10 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Artificial intelligence assistant system" (5 trials), "placebo" (5 trials), "Empagliflozin" (3 trials) and "SHR0302" (3 trials). Other intervention names were less common.

The vast majority of trials in "Renmin Hospital of Wuhan University" are 152 trials for "All" genders, 7 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are 70 active trials in "Renmin Hospital of Wuhan University". 12 are not yet recruiting, 44 are recruiting, 12 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 52 completed trials in Renmin Hospital of Wuhan University, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Renmin Hospital of Wuhan University, 8 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 43 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 16 trials, and there were also 41 trials that are defined as “Not Applicable".